About Ansa Biotechnologies
Ansa Biotechnologies is a company based in Berkeley (United States) founded in 2017 by Sebastian Palluk, Jared Ellefson, and Daniel Lin-Arlow. Ansa Biotechnologies has raised $175.5 million across 8 funding rounds from investors including Mubadala, RA Capital and Northpond Ventures. Ansa Biotechnologies offers products and services including DNA Synthesis Service and Ansa On-Time Guarantee. Ansa Biotechnologies operates in a competitive market with competitors including Twist Bioscience, Nuclera Nucleics, Nutcracker Therapeutics, DNA Script and Sensible Biotechnologies, among others.
- Headquarter Berkeley, United States
- Founders Sebastian Palluk, Jared Ellefson, Daniel Lin-Arlow
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$175.5 M (USD)
in 8 rounds
-
Latest Funding Round
$54.4 M (USD), Series B
Oct 02, 2025
-
Investors
Mubadala
& 16 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ansa Biotechnologies
Ansa Biotechnologies offers a comprehensive portfolio of products and services, including DNA Synthesis Service and Ansa On-Time Guarantee.
Enables direct synthesis of complex DNA sequences up to 7.5 kb.
Ensures timely delivery of DNA orders or offers free service.
People of Ansa Biotechnologies
Unlock access to complete
Funding Insights of Ansa Biotechnologies
Ansa Biotechnologies has successfully raised a total of $175.5M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $54.4 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ansa Biotechnologies
Ansa Biotechnologies has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Mubadala, RA Capital and Northpond Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
Early stage life sciences sectors focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Investment firm focused on finance and technology opportunities.
|
Locked | Locked | Locked |
Investor details for Ansa Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ansa Biotechnologies
Investment portfolio details for Ansa Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ansa Biotechnologies
Detailed financials for Ansa Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ansa Biotechnologies Comparisons
Peer comparison for Ansa Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ansa Biotechnologies
Ansa Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Twist Bioscience, Nuclera Nucleics, Nutcracker Therapeutics, DNA Script and Sensible Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Synthetic DNA is synthesized via a semiconductor-based platform.
|
|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
mRNA therapeutics are developed via proprietary biochip platforms.
|
|
| Locked | Locked | Locked |
Benchtop DNA printers for nucleic acid synthesis are developed.
|
|
| Locked | Locked | Locked |
Developer of mRNA technology for therapeutics and vaccines
|
Detailed competitors of Ansa Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ansa Biotechnologies
Complete news archive for Ansa Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ansa Biotechnologies
Ansa Biotechnologies was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Ansa Biotechnologies is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Jason T Gammack is the current CEO of Ansa Biotechnologies.
Ansa Biotechnologies is a funded company, having raised a total of $175.5M across 8 funding rounds to date.
Ansa Biotechnologies was founded in 2017 in Berkeley, United States. Operations are conducted in the biotechnology sector, where DNA synthesis is facilitated through enzyme-based methods. A chemical approach and next-generation technology are utilized, relying on polymerase-nucleotide conjugates to extend DNA molecules by one building block sequentially. Services are centered on advancing molecular synthesis capabilities in a research-oriented environment.
Ansa Biotechnologies's top competitors include Nuclera Nucleics, Twist Bioscience and Sensible Biotechnologies.
Ansa Biotechnologies offers DNA Synthesis Service and Ansa On-Time Guarantee.
Ansa Biotechnologies has 17 investors. Key investors include Mubadala, RA Capital, Northpond Ventures, Altitude Life Science Ventures, and PEAK6.